Vivace Therapeutics, Inc

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1/2
TEADSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
May 2028 (1)
VT3989Phase 3Pleural Mesothelioma, Mesothelioma
Est. primary completion 2028-05-01 · NCT07824986 · CT.gov ↗
What to watch
2029 (1)
November 2029 (1)
VT3989Phase 1/2Solid Tumor, Adult, Mesothelioma, NSCLC, Pleural Mesothelioma, Non-Pleural Mesothelioma, Non Small Cell Lung Cancer …
Est. primary completion 2029-11-02 · NCT04665206 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.